Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia

Anticancer Res. 2015 Mar;35(3):1697-701.

Abstract

Aim: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP).

Patients and methods: A total of 67 patients treated with vinorelbine and cisplatin as a first-line chemo therapy between January 2002 and December 2013 were retrospectively reviewed.

Results: The overall response rate was 34.3% [95% confidence interval (CI)=22.9%-45.7%). The median progression-free survival, median overall survival, and 1-year survival rates were 3.7 months (95% CI=3.1-4.3 months), 7.4 months (95% CI=5.4-9.4 months), and 22.4% (95% CI=12.4%-32.4%), respectively. The incidence of acute exacerbation of IP following first-line chemotherapy was 10.4%.

Conclusion: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis.

Keywords: Acute exacerbation; cisplatin; interstitial pneumonia; non-small cell lung cancer; vinorelbine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Female
  • Humans
  • Lung Diseases, Interstitial / complications*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Retrospective Studies
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects
  • Vinblastine / analogs & derivatives
  • Vinorelbine

Substances

  • Vinblastine
  • Cisplatin
  • Vinorelbine